Vericel to Present at Morgan Stanley Global Healthcare Conference on September 6, 2024

Vericel Corporation, based in Cambridge, Massachusetts, is a prominent company specializing in advanced therapies for sports medicine and severe burn care. It trades on NASDAQ under the ticker symbol VCEL. The company recently announced that its President and CEO, Nick Colangelo, along with CFO Joe Mara, will engage in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. This event is scheduled for Friday, September 6, 2024, at 1:05 p.m. ET. Interested parties can view a webcast of the presentation on the Investor Relations section of Vericel Corporation's official website.

Vericel Corporation is recognized for its cutting-edge contributions to the medical field, particularly in cell therapy and biologics. The company's innovative approach integrates biological advancements with medical technology, resulting in a unique portfolio of treatments aimed at repairing injuries and improving patient outcomes. Their products are well-regarded in the United States, where they serve critical needs in both sports medicine and severe burn care.

Among Vericel’s notable products is MACI®, an autologous cellularized scaffold designed for repairing symptomatic, full-thickness cartilage defects in the knee. This product is particularly beneficial for adults, addressing both single and multiple defects, with or without associated bone involvement. MACI® stands out for its use of autologous cultured chondrocytes on a porcine collagen membrane, providing a personalized and effective treatment option for knee cartilage damage.

Another significant product offered by Vericel is Epicel®, a cultured epidermal autograft. This product serves as a permanent skin replacement for patients who have suffered deep dermal or full-thickness burns covering 30% or more of their total body surface area. Epicel® is a critical option for burn patients, providing a viable solution for severe and extensive burn injuries.

In addition to MACI® and Epicel®, Vericel holds the exclusive rights in North America to distribute NexoBrid® (anacaulase-bcdb). This biological orphan product, which contains proteolytic enzymes, is specifically indicated for the removal of eschar in both adults and pediatric patients with deep partial-thickness and full-thickness burns. NexoBrid® facilitates the debridement process, which is essential for the effective treatment and healing of severe burns.

Vericel’s commitment to innovation in the medical field is evident in its development and marketing of these advanced therapies. The company’s products not only address critical medical needs but also significantly enhance the quality of life for patients suffering from severe injuries.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!